
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | NASDAQ | USD | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZNCF | OTC Markets | USD | Delayed | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZN | London | GBP | Real-time | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Xetra | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed |
For the three months ended 31 March 2022, AstraZeneca plc (ADR) revenues increased 56% to $11.39B. Net income decreased 75% to $386M. Revenues reflect Farxiga segment increase of 60% to $1B, Calquenc segment increase of 98% to $414M, United States segment increase of 79% to $4.13B, Established ROW segment increase from $96M to $1.61B. Net income was offset by acquisition-related costs and credits increase from $0K to $1.18B (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 11390 | 12011 | 9866 | 8220 |
Gross Profit | 9111 | 8942 | 6042 | 6027 |
Operating Income | 878 | -292 | -1674 | 1127 |
Net Income | 386 | -347 | -1652 | 550 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 100273 | 105363 | 107221 | 73641 |
Total Liabilities | 63933 | 66095 | 67477 | 57965 |
Total Equity | 36340 | 39268 | 39744 | 15676 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 3232 | 5963 | 4545 | 2826 |
Cash From Investing Activities | -168 | -11058 | -10145 | 319 |
Cash From Financing Activities | -3740 | 3649 | 4700 | 4558 |
Net Change in Cash | -685 | -1508 | -973 | 7651 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review